National Comprehensive Cancer Network 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study Shows Abiraterone Acetate is Useful Even in Most Aggressive Prostate Cancers; University of Colorado Cancer Center
In 1,048 prostate cancer patients previously treated with docetaxel and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate led to longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer. Results recently published in the Annals of Oncology show that for patients with Gleason score greater than 8, post-docetaxel treatment with abiraterone extended progression-free survival from 5.5 months ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 3, 2015 Category: Cancer & Oncology Source Type: news
Genetic Mutations Differ within a Single Tumor, Study Finds; University of Michigan Comprehensive Cancer Center
When researchers looked at different areas within an individual rectal cancer sample, they found cases in which each area contained different genetic mutations. The findings could have significant implications for treatment recommendations.
Researchers from the University of Michigan Comprehensive Cancer Center used next-generation sequencing techniques to sample the genetic landscape of different geographic areas from tissue samples taken from six patients with rectal cancer.
University o... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 2, 2015 Category: Cancer & Oncology Source Type: news
NCCN Collaborates with Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer
NCCN is collaborating with Bristol-Myers Squibb to promote the advancement of scientific knowledge concerning programmed death-ligand 1 (PD-L1) protein expression and other immune markers in lung cancer.
FORT WASHINGTON, PA - New molecules and pathways with pivotal functions in regulating the immune system have been discovered recently, providing new understanding of how tumor cells avoid the immune system. One of these molecules, named programmed cell death (PD-1), and molecules that interac... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 2, 2015 Category: Cancer & Oncology Source Type: news
Study Provides New Clues about the Diversity of Prostate Cancer Subtypes (Memorial Sloan Kettering Cancer Center)
A multicenter study led by MSK investigators is seeking to better characterize prostate cancer by studying the molecular characteristics of tumor samples. The team found seven subtypes based on genetic and other molecular changes.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 25, 2015 Category: Cancer & Oncology Source Type: news
New Class of RNA Tumor Suppressors Identified (Stanford Cancer Institute)
A pair of RNA molecules originally thought to be no more than cellular housekeepers are deleted in over a quarter of common human cancers, according to researchers at the Stanford University School of Medicine. Breast cancer patients whose tumors lack the RNA molecules have poorer survival rates than their peers.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 23, 2015 Category: Cancer & Oncology Source Type: news
Scientists Identify Strategy to Prevent Renal Failure, Also Hit on Opportunities to Improve Cancer Treatment (Roswell Park Cancer Institute)
Acute kidney injury (AKI), also known as acute renal failure, is one of the main contributors to death and disability worldwide, yet no preventive treatment for the condition has been established. In a new study published in the journal Cell Death and Differentiation, a team of researchers led by scientists from Roswell Park Cancer Institute (RPCI) reports that they have identified 10 genes whose inhibition appears to protect kidney cells. The findings point the way to strategies for preventing ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 23, 2015 Category: Cancer & Oncology Source Type: news
NCCN Foundation
The NCCN Foundation welcomes Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH, as the newest representatives to its Board of Directors.
FORT WASHINGTON, PA - The NCCN Foundation® has appointed three new representatives to its Board of Directors: Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH. There are currently 15 members of the Board of Directors, responsible for the strategic direction for the NCCN Foundation, which obtains funding to publish t... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 22, 2015 Category: Cancer & Oncology Source Type: news
Tumor-suppressor p53 Regulates Protein that Stifles Immune Attack on Cancer (The University of Texas MD Anderson Cancer Center)
A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 20, 2015 Category: Cancer & Oncology Source Type: news
Personalized Drug Screening on the Horizon for Multiple Myeloma Patients (Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine)
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer. The process, developed by scientists at Washington University School of Medicine in St. Louis, also may aid patients with leukemia or lymphoma.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 19, 2015 Category: Cancer & Oncology Source Type: news
Without Prescription Coverage, Some Cancer Patients Do without Even Low-Cost, High-Benefit Drugs (University of Colorado Cancer Center)
A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug coverage. Women with household income below $40,000 were less than half as likely as women with annual household income greater than $70,000 to continue hormonal therapy. Hormonal t... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 19, 2015 Category: Cancer & Oncology Source Type: news
Study Could Result in New Strategies For Treating Juvenile Cancer (St. Jude Children's Research Hospital/University of Tennessee Health Science Center)
Researchers at St. Jude Children's Research Hospital in Memphis found that hereditary genetic mutations account for 8.5% of childhood malignancies, a higher amount than expected. Yet they found a family history of cancer in only 40% of children with such mutations.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 19, 2015 Category: Cancer & Oncology Source Type: news
Possible New Mechanism for Aspirin's Role in Cancer Prevention (Huntsman Cancer Institute at the University of Utah)
Aspirin has been shown to decrease the risk of colorectal cancer and possibly other cancers. However, the risk of side effects, including in some cases severe gastrointestinal bleeding, makes it necessary to better understand the mechanisms by which aspirin acts at low doses before recommending it more generally as a preventative, says Cornelia Ulrich, PhD, Senior Director of Population Sciences at Huntsman Cancer Institute in Salt Lake City.
... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 19, 2015 Category: Cancer & Oncology Source Type: news
Dr. Robert C. Young Joins NCCN Leadership Team
Robert C. Young, MD, has been appointed Interim Vice President of the NCCN Oncology Research Program (ORP).
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) has appointed Robert C. Young, MD, as Interim Vice President of the NCCN Oncology Research Program (ORP).
Dr. Young brings to NCCN more than 45 years of oncology experience. Dr. Young is President of RCY Medicine, a consulting service focused on cancer center productivity, health care quality, and health policy.... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 18, 2015 Category: Cancer & Oncology Source Type: news
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors (UC San Diego Moores Cancer Center)
Human pluripotent stem cells (hPSC) can become any type of cell in the adult body, offering great potential in disease modeling, drug discovery and creating replacement cells for conditions ranging from cardiovascular to Alzheimer's disease.
But that promise comes with a risk: the possibility that transplanted hPSCs might also develop as unwanted tumors. In a new study published November 10, 2015 in the online journal eLIFE, researchers at University of California, San Diego School of Medicin... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 10, 2015 Category: Cancer & Oncology Source Type: news
NCCN Unveils Evidence Blocks for CML and Multiple Myeloma
New visual tool illustrates five dimensions of value within NCCN Guidelines
SAN FRANCISCO, Calif., (October 16, 2105) - The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers, today unveiled its new value initiative-the NCCN Evidence Blocks™, published within new versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myelogenous Leukemia (CML) and Multiple Myeloma.
'I... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - October 18, 2015 Category: Cancer & Oncology Source Type: news
